RxDoctor Payments Data

Stephanie Stockton

Psychiatric/Mental Health · Wichita Falls, TXNPI 1104458108

Payments from drug & device makers

$3,186in general payments, 2019–2025

Across 180 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$706
  • Neurocrine Biosciences, Inc.$532
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$516
  • Teva Pharmaceuticals USA, Inc.$259
  • Corium, LLC$142
  • Alkermes, Inc.$139
  • plus $892 from 17 others

What the payments were for

  • Food & beverage$3,02795%
  • Education$1585%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,186 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$108,196
Medicare patients
218
Services billed
1,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole11$12,630
Paroxetine Hcl662$4,735
Divalproex Sodium168$2,819
Buspirone Hcl362$2,573
Quetiapine Fumarate111$1,379
Trazodone Hcl229$1,351
Duloxetine Hcl68$1,131
Donepezil Hcl161$992
Olanzapine14$763
Mirtazapine83$659
Memantine Hcl67$592
Valproic AcidValproic Acid (As Sodium Salt)18$497
Fluoxetine Hcl29$285
Risperidone25$262
Aripiprazole13$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$706$12,63011 claims
Lilly USA, LLCOlanzapine$34$76314 claims
Almatica Pharma LLCSertraline Hcl$41$13933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →